NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has issued a strong statement of support for the U.S. Food and Drug Administration (FDA) following the announcement that the agency is launching a major new initiative. The initiative is designed to develop a novel regulatory framework specifically tailored to navigate the complex scientific and practical hurdles inherent in rare disease drug development and review.
The announcement, released by Pam Gavin, President and Chief Executive Officer of NORD, marks what advocates are calling a pivotal moment for millions of patients and families affected by rare conditions. According to Gavin, the move represents an important and deeply welcome step forward for the entire rare disease community.
In her statement, Gavin congratulated FDA leadership for formally recognizing that the extraordinary, rapid advances taking place in rare disease science must be matched by a continuous evolution in how experimental therapies are evaluated. The organization noted that the agency’s proactive stance is a direct reflection of its responsiveness to the pressing concerns of the rare disease community. These concerns were communicated directly to the Acting Commissioner during high-level discussions held earlier this year in June. For patients and their families—many of whom have endured years, and in some cases generations, of waiting without access to viable treatment options—this new regulatory commitment offers genuine, meaningful hope for future medical progress.
The backdrop of this announcement is rooted in decades of advocacy and legislative milestones. Since its founding in 1983, NORD has steadfastly championed policies designed to accelerate rare disease research and therapeutic innovation. That exact same year, the passage of the landmark Orphan Drug Act fundamentally transformed the landscape of rare disease innovation by establishing vital financial and regulatory incentives to encourage developers to target conditions that had long been overlooked by mainstream pharmaceutical research.
More than four decades later, breathtaking scientific advances have unlocked unprecedented opportunities for targeted therapies, gene editing, and personalized medicine. However, this scientific leap forward has also underscored an urgent, growing need for a regulatory framework that can keep pace with innovation while simultaneously addressing the distinct, often daunting challenges that define rare diseases.
Unlike common conditions with massive patient pools, rare diseases present unique obstacles for clinical researchers. Small patient populations, limited natural history data, high levels of disease heterogeneity, and the frequent absence of established biomarkers or standardized clinical endpoints can make traditional approaches to clinical development extraordinarily difficult or, in many instances, entirely infeasible.
NORD emphasizes that a modern regulatory framework must consistently account for these realities. While maintaining rigorous, uncompromised standards for product safety and clinical effectiveness, such a framework is deemed essential to successfully translating laboratory discoveries into accessible, life-changing treatments for patients who desperately need them.
Within the broader scope of the initiative, NORD has highlighted several specific areas where the FDA’s focus is particularly welcome. The organization praised the agency’s emphasis on strengthening consistency and predictability across various review divisions, incorporating patient perspectives meaningfully throughout the entire development and review lifecycle, drawing upon external scientific and clinical expertise when internal knowledge is tested, and building the necessary institutional knowledge required to support sound, forward-thinking regulatory decision-making. At the same time, NORD cautioned that sustained leadership, adequate staffing, sufficient budgetary resources, and consistent implementation across every level of the agency will be absolute prerequisites for the initiative’s success.
What makes this particular FDA initiative so crucial, according to patient advocates, is the distinct opportunity it provides to move beyond the historical practice of making ad-hoc, case-by-case regulatory accommodations. Instead, the goal is to build a comprehensive, cohesive framework specifically designed around the actual scientific realities of rare conditions.
When traditional clinical trial approaches—such as massive, randomized double-blind studies—are simply not feasible due to a lack of available patients, the medical community needs scientifically rigorous, validated ways to evaluate alternative forms of evidence. NORD stresses that this endeavor is fundamentally not about lowering regulatory standards or compromising on patient safety. Rather, it is entirely about ensuring that the methodological tools and metrics used to demonstrate safety and effectiveness are genuinely appropriate for the specific, highly complex diseases and innovative treatments being evaluated.
Looking ahead, NORD has confirmed its intention to actively participate in the FDA’s upcoming stakeholder engagement process. The organization looks forward to working collaboratively alongside the regulatory agency and the broader rare disease community to help shape the trajectory of this important initiative.
Furthermore, NORD announced that it eagerly anticipates welcoming top FDA leadership—including the Acting Commissioner and key representatives from the FDA’s Rare Disease Innovation Hub—to the upcoming 2026 Rare Diseases and Orphan Products Breakthrough Summit®. The premier event is scheduled to take place from October 25 to October 27 in Washington, D.C. The summit is expected to provide an important, timely early opportunity for the rare disease community to engage directly in face-to-face discussions with FDA leadership, allowing stakeholders to explore the new regulatory framework and its practical implications in much greater detail.
Ultimately, NORD asserts that the true measure of success for this initiative will not be found in initial policy announcements, but rather in whether this high-level commitment translates into tangible outcomes. These outcomes include more consistent regulatory practices across the agency, more effective and predictable pathways for developing therapies, and, most importantly, a tangible increase in the number of approved treatment options available to people living with rare diseases.
As the initiative moves from planning to implementation, NORD stands ready to maintain its partnership with the FDA and the wider rare disease community. The shared objective remains turning this institutional commitment into meaningful, measurable progress, paving the way for safe, effective treatments for the millions of individuals and families who are counting on reform.
